CU20220003A7 - Derivados de imidazo[4,5-c]piridina como agonistas de receptores tipo toll - Google Patents

Derivados de imidazo[4,5-c]piridina como agonistas de receptores tipo toll

Info

Publication number
CU20220003A7
CU20220003A7 CU2022000003A CU20220003A CU20220003A7 CU 20220003 A7 CU20220003 A7 CU 20220003A7 CU 2022000003 A CU2022000003 A CU 2022000003A CU 20220003 A CU20220003 A CU 20220003A CU 20220003 A7 CU20220003 A7 CU 20220003A7
Authority
CU
Cuba
Prior art keywords
imidazo
toll
receptor agonists
pyridine derivatives
formula
Prior art date
Application number
CU2022000003A
Other languages
English (en)
Inventor
Omar Ahmad
Andrew Fensome
Ethan Lawrence Fisher
Erik Alphie Lachapelle
Rayomand J Unwalla
Jun Xiao
Lei Zhang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CU20220003A7 publication Critical patent/CU20220003A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>La invención se refiere a compuestos de fórmula (I):</p> <p>ESPACIO PARA FÓRMULA</p> <p>donde R1 a R4 son como se definen en la descripción. Los compuestos de fórmula (I) pueden inhibir las actividades de los receptores TLR7 y TLR8 y pueden ser útiles en el tratamiento del crecimiento celular anormal, incluido el cáncer.</p>
CU2022000003A 2019-07-17 2020-07-14 Derivados de imidazo[4,5-c]piridina como agonistas de receptores tipo toll CU20220003A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875465P 2019-07-17 2019-07-17
US202062961288P 2020-01-15 2020-01-15
PCT/IB2020/056605 WO2021009676A1 (en) 2019-07-17 2020-07-14 Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits

Publications (1)

Publication Number Publication Date
CU20220003A7 true CU20220003A7 (es) 2022-08-09

Family

ID=71728839

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000003A CU20220003A7 (es) 2019-07-17 2020-07-14 Derivados de imidazo[4,5-c]piridina como agonistas de receptores tipo toll

Country Status (23)

Country Link
US (2) US11339159B2 (es)
EP (1) EP3999507B1 (es)
JP (1) JP7137733B2 (es)
KR (1) KR20220034862A (es)
CN (1) CN114364677B (es)
AU (1) AU2020315210B2 (es)
BR (1) BR112022000341A2 (es)
CA (1) CA3147266C (es)
CL (1) CL2022000032A1 (es)
CO (1) CO2022000259A2 (es)
CR (1) CR20220018A (es)
CU (1) CU20220003A7 (es)
EC (1) ECSP22003665A (es)
ES (1) ES3011282T3 (es)
IL (1) IL289877A (es)
MX (1) MX2022000656A (es)
PE (1) PE20220342A1 (es)
PH (1) PH12022550004A1 (es)
PY (1) PY2037133A (es)
TW (1) TWI755788B (es)
UY (1) UY38786A (es)
WO (1) WO2021009676A1 (es)
ZA (1) ZA202201330B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US11339159B2 (en) * 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2022153157A1 (en) 2021-01-13 2022-07-21 Pfizer Inc. A crystalline form of 2-((4-amino-2-(ethoxymethyl)-6,7-dimethyl-1 h-imidazo[4,5-c]pyridin-1-yl)methyl)-2-methylpropane-1,3-diol free base
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
EP4716685A1 (en) * 2023-05-22 2026-04-01 F. Hoffmann-La Roche AG Imidazo[4,5-c]pyridine compounds for the treatment of cancer
TW202515531A (zh) * 2023-07-07 2025-04-16 美商輝瑞股份有限公司 兩親性ｔｌｒ７／８佐劑及其用途
WO2025094035A1 (en) * 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔４，５−ｃ〕ピリジン−４−アミン
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US20070259881A1 (en) 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
AU2006216686A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
HRP20120895T1 (hr) 2007-05-08 2012-11-30 Astrazeneca Ab Imidazokinolini sa imuno-modulacijskim svojstvima
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
CN104185477B (zh) 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
PT3134402T (pt) * 2014-04-22 2020-07-02 Hoffmann La Roche Compostos de 4-amino-imidazoquinolina
WO2016001810A1 (en) 2014-07-01 2016-01-07 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
SG11201704512PA (en) 2014-12-08 2017-07-28 Hoffmann La Roche 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
MX2018007319A (es) 2015-12-14 2018-09-06 Glaxosmithkline Biologicals Sa Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8.
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
US10533007B2 (en) * 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
EP3541219B1 (en) 2016-11-16 2024-01-24 Wink Robotics Eyelid covering and stabilization for automatic eyelash extension
CN108794467A (zh) * 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
US11339159B2 (en) * 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists

Also Published As

Publication number Publication date
CO2022000259A2 (es) 2022-01-17
CA3147266C (en) 2023-09-12
WO2021009676A8 (en) 2022-03-03
JP7137733B2 (ja) 2022-09-14
KR20220034862A (ko) 2022-03-18
US11339159B2 (en) 2022-05-24
CL2022000032A1 (es) 2022-09-02
MX2022000656A (es) 2022-02-16
UY38786A (es) 2021-02-26
PY2037133A (es) 2021-10-01
CA3147266A1 (en) 2021-01-21
EP3999507C0 (en) 2025-01-15
IL289877A (en) 2022-03-01
CN114364677B (zh) 2024-07-09
EP3999507A1 (en) 2022-05-25
AU2020315210A1 (en) 2022-02-03
AU2020315210B2 (en) 2023-01-12
EP3999507B1 (en) 2025-01-15
CR20220018A (es) 2022-02-08
TW202116770A (zh) 2021-05-01
TWI755788B (zh) 2022-02-21
WO2021009676A1 (en) 2021-01-21
ECSP22003665A (es) 2022-02-25
BR112022000341A2 (pt) 2022-04-12
US20210017172A1 (en) 2021-01-21
JP2022534125A (ja) 2022-07-27
PE20220342A1 (es) 2022-03-14
US11976064B2 (en) 2024-05-07
PH12022550004A1 (en) 2022-11-14
ES3011282T3 (en) 2025-04-07
US20220274986A1 (en) 2022-09-01
CN114364677A (zh) 2022-04-15
ZA202201330B (en) 2022-10-26

Similar Documents

Publication Publication Date Title
CU20220003A7 (es) Derivados de imidazo[4,5-c]piridina como agonistas de receptores tipo toll
DOP2020000191A (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina
CU20090175A7 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
CU20190010A7 (es) PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS
CO2021006114A2 (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer
NI200700058A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteína quinasa
UY29081A1 (es) Compuestos de aminoheteroarilo enantioméricamente puros como inhibidores de proteína quinasa
ECSP15031579A (es) Lactamas Fusionadas de Arilo y Heteroarilo
ECSP066406A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CU20120101A7 (es) Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
PE20150684A1 (es) Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
CU23847B1 (es) 2-piperidinilo bencimidazoles útiles en el tratamiento del crecimiento celular anormal
UY30874A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica.
AR083751A1 (es) Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer
CU24087B1 (es) Compuestos de carbazol
ECSP23045506A (es) DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
PE20130191A1 (es) Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida
CO2022015448A2 (es) Compuestos de azalactama como inhibidores de hpk1
MX2023010317A (es) Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
CU20130065A7 (es) Derivados de indol
CO2024003401A2 (es) Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias
UY39731A (es) Derivados microbiocidas de 3-(3,4-dihidroisoquinolin-1-il)quinolin/quinoxalina sustituidos como agen
ECSP11011464A (es) Tia-triaza-ciclopentazulenos
CU23666B7 (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteína quinasa